Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Elite Pharma Inc (ELTP)

Elite Pharma Inc (ELTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 658,911
  • Shares Outstanding, K 1,068,273
  • Annual Sales, $ 56,630 K
  • Annual Income, $ 20,110 K
  • EBIT $ 16 M
  • EBITDA $ 18 M
  • 60-Month Beta 0.18
  • Price/Sales 11.65
  • Price/Cash Flow 21.06
  • Price/Book 13.96
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $0.00 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4321 +40.27%
on 10/30/24
0.7200 -15.82%
on 11/18/24
+0.0660 (+12.22%)
since 10/25/24
3-Month
0.2050 +195.66%
on 08/26/24
0.7549 -19.71%
on 10/22/24
+0.4060 (+202.90%)
since 08/23/24
52-Week
0.1213 +399.67%
on 04/23/24
0.7549 -19.71%
on 10/22/24
+0.4491 (+286.05%)
since 11/24/23

Most Recent Stories

More News
Two Smaller Companies Worthy of Your "Attention"

Elite Pharmaceuticals Inc. (ELTP) fits nicely into the nexus of the increasing diagnoses of ADHD and the patent expiration of the branded drug Vyanse in 2023 for its treatment. Elite Pharmaceuticals Inc....

ELTP : 0.6061 (-1.73%)
PRPO : 5.90 (-0.16%)
Elite Pharmaceuticals' Stock Up Despite Q2 Earnings Decline

Shares of Elite Pharmaceuticals, Inc. ELTP have gained 12.2% since the company released its earnings for the quarter ended Sept. 30, 2024, outperforming the S&P 500 index's decline of 2% during the same...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture,...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Conference Call Scheduled for Friday, November 15 at 11:30 AM ESTNorthvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals,...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products,...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products,...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...

ELTP : 0.6061 (-1.73%)
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024

Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)...

ELTP : 0.6061 (-1.73%)

Business Summary

Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended...

See More

Key Turning Points

3rd Resistance Point 0.6374
2nd Resistance Point 0.6287
1st Resistance Point 0.6174
Last Price 0.6061
1st Support Level 0.5974
2nd Support Level 0.5887
3rd Support Level 0.5774

See More

52-Week High 0.7549
Last Price 0.6061
Fibonacci 61.8% 0.5129
Fibonacci 50% 0.4381
Fibonacci 38.2% 0.3633
52-Week Low 0.1213

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar